安妥来利^®和安妥来^® （米吉珠单抗注射液系列）

健康受试者中单次2 mL与两次1 mL皮下注射米吉珠单抗的生物等效性研究

One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants

发表日期：2025-11-28

健康受试者中米吉珠单抗皮下注射后自动注射器与预充式注射器的药代动力学桥接研究

Pharmacokinetic Bridging Between an Autoinjector and a Prefilled Syringe Following Subcutaneous Administration of Mirikizumab in Healthy Participants

发表日期：2025-09-03

米吉珠单抗原配方与无柠檬酸盐配方皮下注射的药代动力学可比性及安全性：三项临床研究结果

Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical Trials

发表日期：2025-03-21

米吉珠单抗对克罗恩病患者的患者报告结局及生活质量的影响：2 期 SERENITY 研究结果

Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study

发表日期：2026-03-11

用于评估溃疡性结肠炎疾病活动度及早期治疗应答的中性粒细胞检测、定位与定量：一种新型 AI 驱动模型

Detection, localisation, and quantification of neutrophils to assess disease activity and early response to therapy in ulcerative colitis: a novel AI-driven model

发表日期：2025-11-25

米吉珠单抗在中重度活动性溃疡性结肠炎儿童患者中的疗效和安全性（SHINE-1）：一项多中心、开放标签、非随机 2 期研究

Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial

发表日期：2025-11-19

内镜-组织学基础融合模型：一种用于溃疡性结肠炎临床研究中评估组织学缓解及治疗应答的新型人工智能模型

Endo-Histo foundational fusion model: a novel artificial intelligence for assessing histologic remission and response to therapy in ulcerative colitis clinical trial

发表日期：2025-06-23

米吉珠单抗在中重度活动性溃疡性结肠炎儿童患者中的药代动力学及暴露-反应关系

Mirikizumab pharmacokinetics and exposure-response in pediatric patients with moderate-to-severe ulcerative colitis

发表日期：2024-12-18

米吉珠单抗对中重度活动性克罗恩病患者疲乏的持续影响：2期AMAG研究结果

Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study

发表日期：2024-08-02

米吉珠单抗对克罗恩病组织学缓解的影响：一项随机对照 2 期临床试验

Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial

发表日期：2023-11-20

基于机器学习的溃疡性结肠炎内镜Mayo评分预测模型的构建

Development of a Novel Ulcerative Colitis Endoscopic Mayo Score Prediction Model Using Machine Learning

发表日期：2023-10-02

米吉珠单抗在溃疡性结肠炎患者活检样本中诱导的转录组变化自第12周起持续维持至第52周

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52

发表日期：2023-08-18

健康相关生活质量的变化及其与临床疗效改善的关系：米吉珠单抗治疗溃疡性结肠炎患者的 2 期研究

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis

发表日期：2023-03-31

米吉珠单抗调控与溃疡性结肠炎疾病活动度及抗 TNF 耐药相关的基因：一项 2 期研究结果

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study

发表日期：2023-03-07

米吉珠单抗在克罗恩病患者中的长期疗效和安全性：VIVID-2 开放标签扩展研究结果

Mirikizumab Long-Term Efficacy and Safety in Patients With Crohn's Disease: Results From the VIVID-2 Open-Label Extension Trial

发表日期：2026-03-05

米吉珠单抗治疗溃疡性结肠炎的四年持久疗效和安全性：LUCENT-3开放标签扩展研究最终结果

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

发表日期：2026-03-02

溃疡性结肠炎内镜评分中混合型机器学习-人工裁定模式的比较评估

Comparative evaluation of a hybrid machine learning-human adjudication paradigm for endoscopic scoring in ulcerative colitis

发表日期：2025-12-08

米吉珠单抗在中重度活动性克罗恩病患者中的药代动力学及暴露-反应关系：两项随机研究的结果

Mirikizumab Pharmacokinetics and Exposure-Response in Patients With Moderately to Severely Active Crohn's Disease: Results from Two Randomized Studies

发表日期：2025-08-13

克罗恩病中的排便急迫感：米吉珠单抗在一项随机对照3期研究中的疗效

Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study

发表日期：2025-07-14

米吉珠单抗对中重度活动性溃疡性结肠炎患者实现疾病清除的影响：LUCENT 研究中一项预设终点的分析

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint

发表日期：2025-07-13

溃疡性结肠炎中的排便急迫感：基线急迫感及米吉珠单抗治疗后急迫感变化的影响

Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab

发表日期：2025-07-01

粪钙卫蛋白和 C 反应蛋白与米吉珠单抗治疗的溃疡性结肠炎患者组织学和内镜终点的相关性

Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis

发表日期：2025-06-14

米吉珠单抗对中重度活动性克罗恩病患者疲乏的影响：3期VIVID-1研究结果

Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study

发表日期：2025-06-10

米吉珠单抗改善中重度活动性克罗恩病患者的生活质量和工作效率：3期VIVID-1研究结果

Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study

发表日期：2025-03-13

米吉珠单抗在中重度活动性溃疡性结肠炎患者中的长期安全性：一项汇总的两年安全性分析

Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis

发表日期：2025-03-13

由克罗恩病活动指数中的排便频率及腹痛条目构成的患者报告结局指标：克罗恩病成人患者的心理测量学评估

A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn's Disease Activity Index: psychometric evaluation in adults with Crohn's disease

发表日期：2025-02-17

不论基线改良 Mayo 评分如何，米吉珠单抗在中重度活动性溃疡性结肠炎患者中的疗效与安全性：3 期 LUCENT 研究结果

Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials

发表日期：2025-01-08

排便急迫感数字评分量表（Urgency NRS）：克罗恩病成人患者的心理测量学评估

The Urgency Numeric Rating Scale: Psychometric Evaluation in Adults with Crohn's Disease

发表日期：2024-12-18

退出访谈：探索中重度克罗恩病成人患者在米吉珠单抗3期临床试验期间的症状改变体验

Exit Interviews Exploring Patients' Experience of Change in Crohn's Disease Symptoms During the Mirikizumab Phase 3 Clinical Trial In Adult Patients With Moderately-to-Severely Crohn's Disease

发表日期：2024-12-16

米吉珠单抗连续治疗 104 周后的两年疗效与安全性：LUCENT-3 溃疡性结肠炎开放标签扩展研究结果

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

发表日期：2024-12-01

米吉珠单抗治疗中重度活动性克罗恩病的疗效和安全性：一项3期、多中心、随机、双盲、安慰剂及活性对照、全程治疗研究

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

发表日期：2024-11-21

慢性疾病治疗功能评估-疲乏量表（FACIT-Fatigue）在中重度活动性克罗恩病成人患者中的心理测量学评估

Psychometric evaluation of the Functional Assessment of chronic illness therapy-fatigue (FACIT-Fatigue) in adults with moderately to severely active Crohn's disease

发表日期：2024-11-13

米吉珠单抗连续治疗溃疡性结肠炎152周后的三年疗效与安全性：LUCENT-3开放标签扩展研究结果

Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

发表日期：2024-10-25

溃疡性结肠炎患者米吉珠单抗给药的患者及医务人员满意度、可接受性与偏好体验：一项国际调查研究

Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey

发表日期：2024-10-04

米吉珠单抗作为诱导及维持治疗在日本中重度活动性溃疡性结肠炎患者中的疗效与安全性：III期LUCENT-1和LUCENT-2全球研究的亚组分析

Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies

发表日期：2024-04-25

米吉珠单抗在中重度活动性溃疡性结肠炎患者中的药代动力学特征：III 期 LUCENT 研究结果

Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies

发表日期：2023-08-23

米吉珠单抗促进溃疡性结肠炎组织学炎症缓解：LUCENT诱导及维持治疗研究项目结果

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes

发表日期：2023-04-14

溃疡性结肠炎患者排便急迫感数字评分量表作为一种新的患者报告结局指标的心理测量学评估

Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis

发表日期：2023-01-03